相关实验视频
Updated: May 7, 2026
10:12
Designing Porous Silicon Films as Carriers of Nerve Growth Factor
Published on: January 25, 2019
9.7K
一种基于软水凝的C5a酸酶药物递送系统,用于治疗牛皮
Pratikkumar Patel1, Promita Bhattacharjee1, Vinayakumar Gedi1
1Department of Chemical Sciences, Bernal Institute, University of Limerick, Ireland.
International journal of pharmaceutics
|January 27, 2025
概括
这项研究开发了一种长效的C5a酶 (ScpA) 水凝配方,通过向干扰素 (IFN-γ) 来治疗炎症. 这种新型配方有效地提供了多达8天的活性ScpA,显示出治疗潜力.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 药物输送系统 药物输送系统
背景情况:
- 干扰素 (IFN-γ) 是一种关键的促炎细胞因子,与各种炎症性疾病有关.
- 来自Streptococcus pyogenes的C5a酶 (ScpA) 将IFN-γ切割成不活跃的碎片,提供了一个治疗途径.
- 开发持续释放配方对于治疗酶的有效局部输送至关重要.
研究的目的:
- 用Poloxamer 407.7开发一种长效的ScpA现场凝配方,使用Poloxamer 407.
- 评估通过水凝输送的ScpA的稳定性,释放动力学和治疗疗效.
- 评估该配方在治疗IFN-γ介导的炎症状况方面的安全性和潜力.
主要方法:
- 波洛克萨默407和德克斯被配制成一种热反应性水凝,用于in-situ凝.
- 随着时间的推移,从水凝中评估了ScpA的释放特征和酶活性.
- 细胞毒性使用人类不朽化角细胞细胞系进行了评估.
- 使用体外牛皮皮肤模型来评估ScpA水凝配方的治疗疗效.
主要成果:
- 使用Poloxamer 407和Dextran,可以获得具有紧微观结构的稳定水凝.
- 该配方可使活性ScpA持续释放长达8天,而不会损失酶活性.
- 从水凝中释放的ScpA没有观察到细胞毒性.
- 在体外牛皮皮肤模型中,ScpA水凝配方有效地恢复了健康,相当于多剂量自由酶.
结论:
- 基于Poloxamer 407的水凝提供了一个可行的平台,用于长期作用的ScpA.
- 这种配方显示出局部治疗IFN-γ驱动的炎症状况的潜力.
- 开发的水凝为持续的治疗酶递送提供了一个有希望的方法.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...